astragaloside IV

Astragaloside IV

Overview

Astragaloside IV (AS-IV) is a naturally occurring cycloartane-type triterpenoid saponin isolated primarily from Astragalus membranaceus (Astragalus radix, AR), a root herb widely used in traditional Chinese medicine. Structurally, it belongs to the astragaloside family — a group of bioactive saponins that includes astragaloside I (AS-I), astragaloside II (AS-II), astragaloside III (AS-III), and the aglycone cycloastragenol (CA) — each exhibiting distinct pharmacological profiles and in vivo exposure characteristics. AS-IV is recognized for its anti-inflammatory, neuroprotective, and cardioprotective properties, and has attracted substantial research interest as a candidate for multi-symptom therapeutic strategies in complex chronic diseases.

Mechanistically, AS-IV exerts its effects through modulation of inflammatory signaling cascades, mitochondrial biogenesis pathways, and energy metabolism networks. A key molecular target is toll-like receptor 4 (TLR4), a pattern recognition receptor central to innate immune activation and neuroinflammation. By suppressing TLR4-mediated signaling, AS-IV can attenuate the production of proinflammatory cytokines and downstream inflammatory cascades. Additionally, AS-IV influences mitochondrial-synaptic homeostasis through axes such as GSK-3β/PGC-1α, situating it as a compound capable of addressing both upstream inflammatory triggers and downstream metabolic and synaptic dysfunction.

Focus of Latest Publications

Recent literature has positioned astragaloside IV at the intersection of several active therapeutic areas, with studies examining its role in neurodegeneration, cardiovascular protection, and traditional medicine quality standardization.

Parkinson's disease (Motor and Non-Motor Deficits) A 2026 study published in International Immunopharmacology (PMID: 41846059) investigated AS-IV as a therapeutic candidate for Parkinson's disease (PD), focusing on its capacity to simultaneously ameliorate motor deficits and anxiety-like behaviors — two of the most debilitating symptom clusters in PD. The study demonstrated that AS-IV targets TLR4-mediated neuroinflammation as a unified mechanistic pathway capable of addressing both motor and non-motor manifestations of the disease. By suppressing TLR4 signaling, AS-IV reduced the burden of proinflammatory cytokines in the central nervous system, suggesting a multi-symptom therapeutic profile that is particularly valuable in a disease as multifaceted as PD. The authors concluded that AS-IV represents a promising candidate for unified anti-inflammatory intervention in PD.

Alzheimer's Disease (Mitochondrial Biogenesis and Synaptic Preservation) A study in Biomedicine & Pharmacotherapy (PMID: 41934898) explored a multi-target strategy for Alzheimer's disease (AD) combining icariin, AS-IV, and puerarin — collectively termed the Ying-Huang-Ge (YHG) mixture. This combination was shown to salvage synaptic loss by enhancing mitochondrial biogenesis through the GSK-3β/PGC-1α signaling axis. Mitochondrial dysfunction and synaptic deterioration are closely linked hallmarks of Alzheimer's disease, and the YHG mixture addressed both by restoring mitochondrial-synaptic homeostasis. The inclusion of AS-IV in this formulation reflects its recognized role in supporting mitochondrial function, with downstream effects on adenosine triphosphate production and neuronal energy supply — factors critical to maintaining synaptic integrity in AD.

Cardiovascular Protection and Energy Metabolism AS-IV was identified as one of the active constituents of Yangxinshi Tablet (YXS) in a study published in the Chinese Journal of Natural Medicines (PMID: 42062031) that examined post-myocardial infarction heart failure with reduced ejection fraction. Using an oxygen-glucose deprivation (OGD)-induced H9c2 cardiomyocyte injury model, the study identified AS-IV — alongside senkyunolide H, apigenin, and astragaloside VII — as an active compound contributing to the cardioprotective effects of YXS. The protective mechanism was linked to improved energy metabolism through inhibition of the FOXO1/PDK4 signaling pathway, underscoring AS-IV's role in preserving cardiac bioenergetics under ischemic stress.

Pharmacokinetics and Quality Marker Discovery in Astragalus Radix A 2026 study in the Journal of Ethnopharmacology (PMID: 41734824) took a pharmacokinetic approach to evaluating the significance of astragalosides — including AS-IV — within Astragalus radix. By analyzing in vivo exposure levels of prototype saponins and their Metabolites, the study aimed to discriminate and confirm quality markers (Q-markers) among the astragaloside family. This strategy integrated metabolite profiling with pharmacokinetic characteristics to rank the biomedical relevance of individual saponins, with AS-IV, AS-I, AS-II, AS-III, and cycloastragenol each assessed for their distinct pharmacological contributions and systemic exposure profiles.

Phytochemical Fingerprinting and Quality Control (Yupingfeng) A related study in Biomedical Chromatography (PMID: 41925119) evaluated quality markers in the traditional Chinese formula Yupingfeng, which contains Astragalus radix as a key ingredient. While AS-IV was contextually referenced in this phytochemical investigation, the primary Q-markers identified for Yupingfeng included prim-O-glucosylcimifugin, calycosin-7-O-glucopyranoside, and formononetin, among others. This work illustrates the broader chromatographic and analytical framework within which AS-IV is standardized and quality-controlled in complex herbal formulations.

Key Publications

May Discrimination of the significance of astragalosides in Astragalus radix based on the in vivo exposure levels and pharmacokinetic characteristics of prototype saponins and their metabolites: A strategy for discovering and confirming quality markers. (Journal of ethnopharmacology, 2026, PMID 41734824): "Astragaloside Ⅰ (ASⅠ), astragaloside Ⅱ (ASⅡ), astragaloside Ⅲ (ASⅢ), astragaloside Ⅳ (ASⅣ), and cycloastragenol (CA) in AR exhibit diverse pharmacological activities."
May Astragaloside IV alleviates motor and anxiety deficits in Parkinson's disease mice by targeting TLR4. (International immunopharmacology, 2026, PMID 41846059): "Our findings highlight AS-IV as a promising multi-symptom therapeutic candidate for PD, capable of addressing both motor and non-motor deficits through a unified anti-inflammatory mechanism."
May Identification and Multidimensional Evaluation of Quality Markers in Yupingfeng via UPLC-Q-Orbitrap-MS, Network Pharmacology, UPLC-UV Fingerprint, and UPLC-QQQ-MS. (Biomedical chromatography : BMC, 2026, PMID 41925119): "Finally, 10 compounds, including prim-O-glucosylcimifugin, calycosin-7-O-glucopyranoside, cimifugin, 5-O-methylvisammioside, ononin, sec-O-glucosylhamaudol, calycosin, astragaloside A, formononetin, and atractylenolide II, were identified as the Q-markers of YPF, and a rapid UPLC-QQQ-MS method was developed for their simultaneous determination."
May Yangxinshi Tablet protects against post-myocardial infarction heart failure with reduced ejection fraction by improving energy metabolism through inhibition of FOXO1/PDK4 signaling. (Chinese journal of natural medicines, 2026, PMID 42062031): "Senkyunolide H, apigenin, astragaloside IV, and astragaloside VII were identified as active constituents of YXS using an OGD-induced H9c2 cell injury model."
Apr Icariin, astragaloside IV and puerarin mixture salvages synaptic loss by enhancing mitochondrial biogenesis: A multi-target strategy for Alzheimer's disease therapy. (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026, PMID 41934898): "This study aimed to elucidate the potential mechanism by which the Icariin, astragaloside IV and puerarin (Ying-Huang-Ge, YHG) mixture regulates mitochondrial-synaptic homeostasis in Alzheimer's disease (AD) MOD mice through the Glycogen Synthase Kinase-3β (GSK-3β)/Peroxisome Proliferator-Activated Receptor γ Coactivator-1α (PGC-1α) signaling axis."